Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions

Journal of Virology

Volumn 73, Issue 2, 1999, Pages 1156-1164

  Davis, David A ^a   Yusa, Keisuke ^a   Gillim, Laura A ^a   Newcomb, Fonda M ^a   Mitsuya, Hiroaki ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYSTEINE; DITHIOTHREITOL; KYNOSTATIN 272; PROTEIN; PROTEINASE;

ARTICLE; ELECTRON MICROSCOPY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; MATURATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN PROCESSING; VIRION; VIRUS PARTICLE;

EID: 0032902555     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.2.1156-1164.1999     Document Type: Article

References (46)

1. Bechtold, C. M., A. K. Patick, M. Alam, J. Greytok, J. A. Tino, P. Chen, E. Gordon, S. Ahmad, J. C. Barrish, R. Zahler, P.-F. Lin, and R. Colonno. 1995. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob. Agents Chemother. 39:374-379.
2. Buttke, T. M., and P. A. Sandstrom. 1995. Redox regulation of programmed cell death in lymphocytes. Free Radic. Res. 22:389-397.
3. Camaur, D., and D. Trono. 1996. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J. Virol. 70:6106-6111.
4. Darke, P. L., C.-T. Leu, L. J. Davis, J. C. Heimbach, R. E. Diehl, W. S. Hill, A. F. Dixon, and I. S. Sigal. 1989. Human immunodeficiency virus protease: bacterial expression and characterization of the purified aspartic protease. J. Biol. Chem. 264:2307-2312.
5. Davis, D. A., A. A. Branca, A. J. Pallenberg, T. M. Marschner, L. M. Patt, L. G. Chatlynne, R. W. Humphrey, R. Yarchaon, and R. L. Levine. 1995. Inhibition of human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulphonic acid copper. Arch. Biochem. Biophys. 322:127-134.
6. Davis, D. A., K. Dorsey, P. T. Wingfield, S. J. Stahl, J. Kaufman, H. M. Fales. and R. L. Levine. 1996. Regulation of HIV-1 protease activity through cysteine modification. Biochemistry 35:2482-2488.
7. Davis, D. A., F. M. Newcomb, D. W. Starke, D. E. Ott, J. M. Mieyal, and R. Yarchoan. 1997. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. J. Biol. Chem. 272:25935-25940.
8. Gelderblom, H. R., M. Ozel, and G. Pauli. 1989. Morphogenesis and morphology of HIV: structure function relations. Arch. Virol. 106:1-13.
9. Goobar-Larsson, L., B. G. Luukkonen, T. Unge, S. Schwartz, G. Utter, B. Strandberg, and B. Oberg. 1995. Enhancement of HIV-1 proteinase activity by HIV-1 reverse transcriptase. Virology 206:387-394.
10. Grant, S. K., I. C. Deckman, M. D. Minnich, J. S. Culp, S. Franklin, G. B. Dreyer, T. A. Tomaszek, C. Debouck, and T. D. Meek. 1991. Purification and biochemical characterization of recomhinant simian immunodeficiency virus protcase and comparison to human immunodeficiency virus type 1 protcase. Biochemistry 30:8424-8434.
11. Humphrey, K. W., A. Ohagen, D. A. Davis, T. Fukazawa, H. Hayashi, S. Höglund, H. Mitsuya and R. Yarchoan. 1997. Removal of human immunodeficiency virus type 1 (HIV-1) protcase inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology. Antimicrob. Agents Chemother. 41: 1017-1023.
12. Johnson, V. A., and R. E. Byington. 1990. Quantitative assays for virus infectivity. p. 71-76. In A. Aldovini and B. D. Walker (ed.). Techniques in HIV research. Stockton Press. New York, N.Y.
13. Kageyama. S., D. T. Hoekzema, Y. Murakawa, E. Kojima, T. Shirasaka, D. J. Kempf, D. W. Norbeck, J. Erickson and H. Mitsuya. 1994. A C2 symmetry-based HIV protease inhibitor. A77003. irreversibly inhibits infectivity of HIV-1 in vitro. AIDS Res. Hum. Retroviruses 10:735-743.
14. Kageyama, S., T. Mimoto, Y. Murakawa, M. Nomizu, H. Ford, Jr., T. Shirasaka, S. Gulnik, J. Erickson, K. Takada, H. Hayashi, S. Broder, Y. Kiso. and H. Mitsuya. 1993. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother. 37:810-817.
15. Kaplan, A. H., M. Manchester, and R. Swanstrom. 1994. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68:6782-678.
16. Kaplan, A. H., and R. Swanstrom. 1991. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc. Natl. Acad. Sci. USA 88:4528-4532.
17. Kaplan, A. H., J. A. Zack, M. Knigge, D. A. Paul, D. J. Kempf, D. W. Norbeck, and R. Swanstrom. 1993. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67:4050-4055.
18. Karacostas, V., E. J. Wolffe, K. Nagashima, M. A. Gonda, and B. Moss. 1993. Overexpression of the HIV-1 Gag-Pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 193:661-671.
19. Karlstrom, A. R., and R. L. Levine. 1991. Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms. Proc. Natl. Acad. Sci. USA 88:5552-5556.
20. Karlstrom, A. R., B. D. Shames, and R. L. Levine. 1993 Reactivity of cysteine residues in the protease from human immunodeficiency virus: identification of a surface-exposed region which affects enzyme function. Arch. Biochem. Biophys. 304:163-169.
21. Katsumoto, T., N. Hattori, and T. Kurimura. 1987. Maturation of human immunodeficiency virus, strain LAV. in vitro. Intervirology 27:148-153.
22. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. F. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85: 4686-4690.
23. Kosower, N. S., E. M. Kosower, and B. Wertheim. 1969. Diamide, a new reagent for the intracellular oxidation of glutathione to the disulfide. Biochem. Biophys. Res. Commun. 37:593-596.
24. Kotler, M., M. Simm, Y. S. Zhao, P. Sova, W. Chao, S.-F. Ohnona, R. Roller, C. Krachmarov, M. J. Potash, and D. J. Volsky. 1997. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J. Virol. 71:5774-5781.
25. Kräusslich, H.-G. 1992. Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J. Virol. 66:567-572.
26. Kurata, S. 1996. Sensitization of the HIV-1-LTR upon long term low dose oxidative stress. J. Biol. Chem. 271:21798-21802.
27. Lambert, D. M., S. R. Petteway, Jr., C. E. McDanal, T. K. Hart, J. J. Leary. G. B. Dreyer, T. D. Meek, P. J. Bugelski, D. P. Bolognesi, B. W. Metcalf, and T. J. Matthews. 1992. Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob. Agents Chemother. 36:982-988.
28. Gag Pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Virology 214:624-627.
29. McCune, J. M., L. B. Rabin, M. B. Feinberg, M. Lieberman, J. C. Kosek, G. R. Reyes, and I. L. Weissman. 1988. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53:55-67.
30. McQuade, T. J., A. G. Tomasselli, L. Liu, V. Karacostas, B. Moss, and T. Sawyer. 1990. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247:454-156.
31. Meek, T. D., B. D. Dayton, B. W. Metcalf, G. B. Dreyer, J. E. Strickler, J. E. Gorniak, M. Rosenberg, M. L. Moore, V. M. Magaard, C. Debouck. 1989. Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. Proc. Natl. Acad. Sci. USA 86:1841-1845.
32. Patick, A. K., H. Mo, M. Markowitz, K. Appell, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Antiviral and resistance studies of AG1343. an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297.
33. Piette, J., and S. Legrand-Poels. 1994. HIV-1 reactivation after an oxidative stress mediated by different reactive oxygen species. Chem. Biol. Interact. 91: 79-89.
34. Rayner, M. M., B. C. Cordova, R. P. Meade, P. E. Aldrich, P. K. Jadhav, Y. Ru, and P. Y. S. Lam. 1994. DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein. Antimicrob. Agents Chemother. 38:1635-1640.
35. Richards, A. D., L. H. Phylip, W. G. Farmerie, P. E. Scarborough, A. Alvarez, B. M. Dunn, P. H. Hirel, J. Konvalinka, P. Strop, L. Pavlickova, L. Kostka, and J. Kay. 1990. Sensitive, soluble chromogenic substrates for HIV-1 proteinase. J. Biol. Chem. 265:7733-7736.
36. Sappey, C., S. Legrand-Poels, M. Best-Belpomme, A. Favier, B. Rentier, and J. Piette. 1994. Stimulation of glutathione peroxidase activity decreases HIV type I activation after oxidative stress. AIDS Res. Hum. Retroviruses 10: 1451-1461.
37. Schatzl, H., H. R. Gelderblom, H. Nitschko, and K. von der Helm. 1991. Analysis of non-infectious HIV particles produced in presence of HIV proteinase. Arch. Virol. 120:71-81.
38. Schuppe, I., P. Moldeus, and I. A. Cotgreave. 1992. Proteinspecific s-thiolation in human endothelial cells during oxidative stress. Biochem. Pharmacol. 44:1757-1764.
39. Sheng, N., S. C. Pettit, R. J. Tritch, D. H. Ozturk, M. M. Rayner, R. Swanstrom, and S. Erickson-Viitanen. 1997. Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J. Virol. 71:5723-5732.
40. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
41. Terada, T., T. Oshida, M. Nishimura, H. Maeda, T. Hara, S. Hosomi, T. Mizoguchi, and T. Nishihara. 1992. Study on human erythrocyte thioltransferase: comparative characterization with bovine enzyme and its physiological role under oxidative stress. J. Biochem. (Tokyo) 111:688-692.
42. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
43. Vance, J. E., D. A. LeBlanc, P. Wingfield, and R. E. London. 1997. Conformational selectivity of HIV-1 protease cleavage of X-Pro peptide bonds and its implications. J. Biol. Chem. 272:15603-15606.
44. Westendorp, M. O., V. A. Shatrov, K. Schulze-Osthoff, R. Frank, M. Kraft, M. Los, P. H. Krammer, W. Droge, and V. Lehmann. 1995. HIV-1 Tat potentiates TNF-induced NF-K B activation and cytotoxicity by altering the cellular redox state. EMBO J. 14:546-554.
45. Yusa, K., M. F. Kavlick, K. Pope, and H. Mitsuya. 1997. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination. Antivir. Res. 36:179-189.
46. Zybarth, G., and C. Carter. 1995. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J. Virol. 69:3878-3884.